Phase I study of adoptive immunotherapy using the cytotoxic natural killer (NK) cell line, NK-92, for treatment of advanced renal cell carcinoma and malignant melanoma. - Arai,S.; Kindy,K.; Swearingen,M.; Meagher,R.; Friend,P.; Maki,G.; Martinson,J.; Myint,H.; Klingemann,HG. (Blood, 2003)